ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Mar 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
April 2026
Nuclear Technology
February 2026
Fusion Science and Technology
Latest News
U.K. vision for fusion
The U.K. government has announced a series of initiatives to progress fusion to commercialization, laid out in a fusion strategy policy paper published March 16. A New Energy Revolution: The UK’s Plan for Delivering Fusion Energy begins to describe how the government’s £2.5 billion (about $3.4 billion) investment in fusion research and development over five years will be allocated.
B.F. Peterman, J.R. Johnson, R.G.C. McElroy
Fusion Science and Technology | Volume 8 | Number 2 | September 1985 | Pages 2557-2563
Environmental Study | Proceedings of the Second National Topical Meeting on Tritium Technology in Fission, Fusion and Isotopic Applications (Dayton, Ohio, April 30 to May 2, 1985) | doi.org/10.13182/FST85-A24664
Articles are hosted by Taylor and Francis Online.
This paper describes a study on metabolism of inhaled tritiated hydrogen gas (HT) in mammals. Rats and human volunteers were exposed to HT gas for periods from one minute to ten minutes. The amount of HT that was oxidized in vivo was estimated by measuring the concentration of HTO in urine. No significant quantities of tritiated organic compounds resulting from HT gas inhalation were observed in tissues of rats and it is assumed that this holds true for humans also. The fraction of inhaled HT converted to HTO in human volunteers was found to be about 1 × 10−4 indicating that the dose from the HTO that resulted from HT oxidiation is a significant component of the effective dose equivalent.